title: Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
abstract: BACKGROUND
  Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment.
  
  
  RESULTS
  The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 microm (week 1), 205 microm (week 4), and 171 microm (week 12), respectively (P < 0.0001, for all comparisons). One patient experienced a transient moderate vision loss after 4 weeks post treatment. Leakage on fluorescein angiography was resolved in all patients at week 12. No significant ocular or systemic side-effects were observed.
  
  
  CONCLUSIONS
  Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.
authors: Department of Ophthalmology, University of Bonn, Ernst-Abbe-Strasse 2, 53127, Bonn, Germany.
authors: Markus S
authors: MS
authors: Ladewig
authors: Stefanie E
authors: SE
authors: Karl
authors: Victoria
authors: V
authors: Hamelmann
authors: Hans-Martin
authors: HM
authors: Helb
authors: Hendrik P N
authors: HP
authors: Scholl
authors: Frank G
authors: FG
authors: Holz
authors: Nicole
authors: N
authors: Eter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003131:Combined Modality Therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D000068258:Bevacizumab
references: Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1132-42
references: 16538452
references: Am J Ophthalmol. 2004 Nov;138(5):803-8
references: 15531316
references: Ophthalmology. 2006 Jan;113(1):14-22
references: 16360209
references: Ophthalmology. 1996 Mar;103(3):427-38
references: 8600419
references: Am J Ophthalmol. 2003 Mar;135(3):343-50
references: 12614752
references: Graefes Arch Clin Exp Ophthalmol. 2003 Jun;241(6):518-21
references: 12734707
references: Br J Ophthalmol. 2004 Mar;88(3):344-7
references: 14977766
references: Am J Ophthalmol. 2003 Sep;136(3):407-18
references: 12967792
references: Arch Ophthalmol. 1999 Sep;117(9):1177-87
references: 10496389
references: Ophthalmology. 2005 Jun;112(6):1035-47
references: 15936441
references: Ophthalmology. 2005 Feb;112(2):301-4
references: 15691567
references: Invest Ophthalmol Vis Sci. 2006 Jan;47(1):371-6
references: 16384987
references: Invest Ophthalmol Vis Sci. 2003 May;44(5):2147-54
references: 12714655
references: Arch Ophthalmol. 2002 Jun;120(6):835-44
references: 12049594
references: Acta Ophthalmol Scand. 2005 Dec;83(6):645-63
references: 16396641
references: Invest Ophthalmol Vis Sci. 1999 Sep;40(10 ):2322-31
references: 10476799
references: Ophthalmology. 2003 Aug;110(8):1517-25
references: 12917166
references: Am J Ophthalmol. 2004 Mar;137(3):504-10
references: 15013875
references: Klin Monbl Augenheilkd. 2005 May;222(5):390-5
references: 15912456
references: Graefes Arch Clin Exp Ophthalmol. 2006 Jul;244(7):773-81
references: 16440207
references: Invest Ophthalmol Vis Sci. 2006 Jan;47(1):357-63
references: 16384985
references: Mol Vis. 2003 Dec 22;9:747-55
references: 14735062
references: Arch Ophthalmol. 1999 Oct;117(10 ):1329-45
references: 10532441
references: Invest Ophthalmol Vis Sci. 2003 Oct;44(10 ):4473-80
references: 14507895
references: Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
references: 16172168
references: Retina. 2006 Apr;26(4):383-90
references: 16603955
references: Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2389-93
references: 10892888
references: Retina. 2004 Oct;24(5 Suppl):S3-19
references: 15483476
references: Ophthalmology. 2006 Mar;113(3):363-372.e5
references: 16458968
references: Arch Ophthalmol. 2001 Feb;119(2):198-207
references: 11176980
references: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
references: 16156152
references: J Clin Invest. 2006 Feb;116(2):422-9
references: 16453023
references: Arch Ophthalmol. 2005 Apr;123(4):509-16
references: 15824225